Zacks Investment Research·3d ago
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in FocusSummit reports Q3 loss narrower than expected and posts nil sales. Ivonescimab advances through late-stage studies and new oncology collaborations.
Summit Therapeutics has pivoted entirely to ivonescimab, a bispecific antibody licensed from Akeso, evidenced by R&D spend rising from $24.5M in 2024Q1 to $157.7M in 2026Q2.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Summit remains pre-revenue with zero sales across all quarters, while R&D and SG&A escalation drove operating losses from -$33.6M in 2024Q1 to -$220.5M in 2026Q2, a 6.6x increase.
The bullish thesis for Summit Therapeutics is anchored in ivonescimab's potential to challenge entrenched standards of care like Keytruda and expand across multiple NSCLC populations.
Ivonescimab may enter entirely new tumor types through RAS combination strategies, broadening its therapeutic applications.
Summit Therapeutics reported new Phase II and Phase III ivonescimab data in colorectal and lung cancer, showing strong objective responses in first-line metastatic colorectal cancer.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.26+7.7% vs -$0.28 | — vs $111,111 |
Q3 2026 Jul 23, 2026 | -$0.28-2.0% vs -$0.27 | — vs $113,889 |
Q2 2026 Apr 30, 2026 | -$0.24+27.3% vs -$0.33 | — vs $54,420 |
Q1 2026 Feb 23, 2026 | -$0.29-182.5% vs -$0.10 | — vs $57M |
Summit reports Q3 loss narrower than expected and posts nil sales. Ivonescimab advances through late-stage studies and new oncology collaborations.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca's $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others,” said Robert W. Duggan, Ch.
The S&P 500 remains in a confirmed uptrend, yet a big slice of the market isn't along for the ride. Money keeps crowding into the same mega-cap leaders, and plenty of solid companies sit below their 50-day moving averages even as their earnings outlooks hold up.
Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
Benchmark SMMT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Summit Therapeutics Inc. (SMMT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.33 | $13.03B | -15.65 | — | — | -158.78% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $192.28 | $40.88B | -22.10 | — | -946.82% | -91.93% | — | |
| $21.50 | $3.5B | -26.04 | 48.29% | -229.92% | -25.74% | — | |
| $300.88 | $8.87B | 41.21 | 33.94% | 47.91% | 17.02% | — | |
| $69.57 | $17.49B | 20.10 | 6.98% | 35.45% | 45.54% | — |
Summit Therapeutics Inc. (SMMT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Summit Therapeutics Inc. (SMMT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 23, 2026·SEC
Jul 23, 2026·SEC
Get notified when SMMT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Summit Therapeutics Inc. (SMMT) stock FAQ — growth, dividends, profitability & financials explained
No. Summit Therapeutics Inc. (SMMT) reported a net loss of $832.7M over the trailing twelve months.
Summit Therapeutics Inc. (SMMT) had a return on equity (ROE) of -158.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Summit Therapeutics Inc. (SMMT) had negative free cash flow of $497.7M over the trailing twelve months.
